MAP2K7 and colorectal carcinoma: We thus hypothesized that AKT and MEK activation is used by CRC cells to promote their survival upon treatment, and that a synergistic effect could be obtained in CRC cells by associating irinotecan with agents that inhibit AKT and MEK, thus allowing to significantly reduce the drug doses.